L2B - Brain cancer
Your external Innovation management to fight brain cancer
Unique combination of scientific, business and patient expertise on GBM and other brain tumors
​
Service eligible for the French government's tax credit “Credit d'Impot Recherche (CIR)”
​
I provide innovation management (R&D and BD) services to:
-
Develop preclinical research plans and manage R&D (See L2B-preclinical services Here) with in depth pharmacological expertise on brain tumors.
-
Help you explore Blood Brain Barrier (BBB) opening and crossing options.
-
Challenge your plans to increase your technology potential for brain tumors patients.
-
Conduct market research: competitive intelligence, product market fit, competitive advantage.
-
Reach out for partners among my extended and active network in the field.
-
Support medical writing and corporate/charity communication activities.
​
Recent project exemples:
-
Program Expert – clinical stage oncology molecule repositioning on GBM and modification for BBB crossing.
-
Project co-lead - efficacy and administration route optimization for a GBM targeting peptide.
-
Project lead: complete market study and startup development plan design for a brain cancer diagnostic solution to switch from a technology push to a demand pull with successful VC traction.
-
Scientific board member for 2 GBM related project, including the patient association DEDLM.
​
My unique value : from Scientist trough caregiver to contributor
One of the rare neuro-oncology preclinical PhD with 10+ years hands-on experience having both:
-
business mindset: with a master from HEC Paris and 3 experiences as C-level executive in the brain tumor era,
-
a patient’s relative experience, bonding with other patients’ families and association to fully understands the clinical practice beyond survival median time.
As a scientist I care about data, embracing complexity.
As a caregiver I integrate subtle emotions, intuition and hope.
As a business woman I’m on a mission to support, accelerate and increase the impact of your solution against brain Cancers by integrating my unique diverse experience.
Our Clients Say
" We called on Sandrine to establish the positioning of a neuroscience drug candidate for brain cancer indications. Sandrine demonstrated a rare ability to get involved quickly and independently in complex projects, which saved us time. She brought cutting-edge expertise in preclinical oncology, mobilized a powerful active network and shared significant ideas that were subsequently confirmed by KoL. The collaboration was fluid, with clear, rapid deliverables and a pleasant team spirit.
In 3 months, we achieved a clear positioning with a strategic vision and a competitive advantage that would have taken much longer without Sandrine.
Most importantly, Sandrine's insights, positive energy and management tools have nourished our global thinking and practices, leaving a lasting positive impact on our scientific and corporate strategy, well beyond the initial objective. "
Xenia Proton de la Chapelle, CEO & Nathan Beckouche CSO, AtmosR, France
Get in Touch
Let's discuss your needs.